Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 0%
Hold 67%
Sell 17%
Strong Sell 0%

Bulls say

Amphastar Pharma is expected to face challenges in the near term from pricing pressure on its Baqsimi product and competition for its generic epinephrine and glucagon products, leading to margin erosion and lower EBITDA estimates. However, the company has a strong pipeline of generic and proprietary products that will continue to drive future success, as the development and commercialization of new products is time-consuming, costly and involves a high degree of risk. An update in the company's valuation methodology has led to a lowered price target of $21, reflecting a multiple of 7x based on the 2027E EBITDA estimate of $204M, discounted by 12% for one year.

Bears say

Amphastar Pharma is currently facing a number of challenges that are negatively impacting its financial performance and outlook. These include pricing headwinds for its flagship product Baqsimi, which has experienced significant erosion in average selling price due to higher rebates and discounts. Additionally, the company is facing competitive pressures in its base generics business, specifically in its injectable glucagon product due to the entry of a new generic competitor. Despite having a number of potential opportunities in its pipeline, the visibility into when these could materialize and contribute to top-line and EBITDA growth is unclear. As a result, the stock is fairly valued at an EV/2027E EBITDA of ~7x, leading to a negative outlook.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.